Q32 Bio Reports 35.3% Mean SALT Reduction at Week 36 in Alopecia Areata Trial
Q32 Bio said on September 30, 2026 that additional 36-week results and initial 16-week off-drug findings from Part B of its open-label SIGNAL-AA Phase 2a trial of bempikibart were presented at the EADV Congress 2026. The Part B study enrolled 33 patients with severe or very severe alopecia areata, and the company plans to start a registration-directed program in the first half of 2027, subject to regulatory discussions in the second half of 2026.
Key points
- At Week 36, mean SALT score reduction from baseline was 35.3% in the mITT analysis, and 40.0% (10/25) of mITT patients achieved a SALT-20 response.
- At the 16-week off-drug time point, 44% of patients achieved SALT-20, 61% achieved SALT 30 and 50% achieved SALT 50 (18 patients entered this period).
- The company reported no serious adverse events or Grade 3 or higher treatment-related adverse events; injection site reactions were the most common treatment-emergent adverse event at 36.3%.
- Q32 Bio plans regulatory discussions in the second half of 2026, a registration-directed program in the first half of 2027, and expects Part B open-label extension data in the second half of 2027.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.